Rhumbline Advisers Immunovant, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Immunovant, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 79,744 shares of IMVT stock, worth $2.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,744

Previous 83,532 4.53%

Holding current value

$2.19 Million

Previous $2.21 Million 0.54%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$27.51 - $27.51 $104,207 - $104,207	-3,788 Reduced 4.53%	79,744 $2.19 Million
Q2 2024 Aug 01, 2024	BUY	$25.1 - $31.61 $184,811 - $232,744	7,363 Added 9.67%	83,532 $2.21 Million
Q1 2024 May 09, 2024	BUY	$30.27 - $43.79 $54,788 - $79,259	1,810 Added 2.43%	76,169 $2.46 Million
Q4 2023 Feb 08, 2024	SELL	$31.31 - $44.19 $6,449 - $9,103	-206 Reduced 0.28%	74,359 $3.13 Million
Q3 2023 Nov 09, 2023	BUY	$18.55 - $39.96 $43,907 - $94,585	2,367 Added 3.28%	74,565 $2.86 Million
Q2 2023 Aug 08, 2023	BUY	$14.2 - $23.75 $7,810 - $13,062	550 Added 0.77%	72,198 $1.37 Million
Q1 2023 May 11, 2023	BUY	$15.27 - $19.72 $27,577 - $35,614	1,806 Added 2.59%	71,648 $1.11 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $49,161 - $132,415	7,460 Added 11.96%	69,842 $1.24 Million
Q3 2022 Nov 10, 2022	BUY	$3.93 - $6.37 $16,533 - $26,798	4,207 Added 7.23%	62,382 $348,000
Q2 2022 Aug 11, 2022	BUY	$3.38 - $5.65 $42,963 - $71,817	12,711 Added 27.96%	58,175 $227,000
Q1 2022 May 12, 2022	SELL	$5.06 - $8.77 $126 - $219	-25 Reduced 0.05%	45,464 $251,000
Q4 2021 Feb 10, 2022	SELL	$7.33 - $9.32 $4,405 - $5,601	-601 Reduced 1.3%	45,489 $388,000
Q3 2021 Nov 12, 2021	BUY	$7.01 - $11.37 $13,178 - $21,375	1,880 Added 4.25%	46,090 $401,000
Q2 2021 Aug 05, 2021	BUY	$9.4 - $16.85 $21,168 - $37,946	2,252 Added 5.37%	44,210 $467,000
Q1 2021 May 06, 2021	SELL	$13.08 - $49.6 $22,955 - $87,048	-1,755 Reduced 4.01%	41,958 $673,000
Q4 2020 Feb 10, 2021	BUY	$36.36 - $52.71 $216,814 - $314,309	5,963 Added 15.8%	43,713 $2.02 Million
Q3 2020 Nov 12, 2020	BUY	$22.61 - $38.9 $335,735 - $577,626	14,849 Added 64.84%	37,750 $1.33 Million
Q2 2020 Aug 13, 2020	BUY	$13.87 - $28.44 $317,636 - $651,304	22,901 New	22,901 $558,000

Others Institutions Holding IMVT

# of Institutions

211

Shares Held

66.9M

Call Options Held

2.3M

Put Options Held

631K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Immunovant, Inc. Transaction History